How Lab-Grown Organs Work—and Why Medicine Needs Them

A Shortage Measured in Lives

More than 100,000 people in the United States alone sit on the national organ transplant waiting list at any given time, according to the U.S. Department of Health and Human Services. Roughly 13 Americans die every day because a matching donor organ never arrives. Kidneys account for the vast majority of the need — nearly 90,000 of those waiting — followed by livers, hearts, and lungs.

Traditional transplantation depends on a limited pool of deceased and living donors. Tissue engineering, the science of building replacement tissues and organs in the laboratory, aims to close that gap by growing what donors cannot supply.

The Three Pillars of Tissue Engineering

Every lab-grown organ relies on three core ingredients: a scaffold, living cells, and biological signals that tell those cells what to become.

Scaffolds — the Organ's Blueprint

A scaffold provides the three-dimensional framework a new organ needs. One widely used method is decellularization: scientists take a donor organ — human or animal — and wash away every cell using detergents and enzymes. What remains is a translucent mesh of proteins called the extracellular matrix (ECM). This ghost-like skeleton preserves the organ's exact shape, its internal channels for blood vessels, and chemical cues that guide new cells into the right positions.

Synthetic scaffolds offer an alternative. Researchers can fabricate structures from biocompatible polymers, or even 3D-print them layer by layer using bioprinting technology — essentially modified inkjet printers loaded with living cells instead of ink.

Cells — Seeding New Life

Once a scaffold is ready, scientists seed it with cells, ideally the patient's own. A tiny tissue biopsy — sometimes no larger than a postage stamp — provides starter cells that are expanded in the lab over several weeks using growth factors. Because these autologous cells carry the patient's own DNA, the finished organ is far less likely to trigger immune rejection, potentially eliminating the need for lifelong immunosuppressive drugs.

Bioreactors — Simulating the Body

Seeded scaffolds are placed inside bioreactors, chambers that mimic conditions inside the body — temperature, oxygen levels, mechanical stress, and nutrient flow. Under these conditions, cells multiply, organize, and mature into functional tissue.

Milestones Already Achieved

The field's first landmark came in 1999 when Anthony Atala's team at Wake Forest Institute for Regenerative Medicine implanted laboratory-grown bladders into young patients with spina bifida. The engineered tissue integrated successfully and restored function — a proof of concept that resonated across medicine.

In 2011, surgeons at Karolinska University Hospital in Stockholm transplanted a synthetic trachea seeded with a patient's own stem cells — the first time a lab-built organ used no donor tissue at all. The scaffold was made from biocompatible nanocomposite material shaped to match the patient's airway.

Most recently, in March 2026, scientists from Great Ormond Street Hospital and University College London reported engineering the first functional lab-grown oesophagus. Using a decellularized pig donor scaffold repopulated with the recipient's own cells, the graft developed muscle, nerves, and blood vessels, restoring normal swallowing in a large-animal model — all without immunosuppression.

The Biggest Remaining Challenges

Vascularization remains the field's toughest hurdle. Simple, thin tissues like skin and bladder lining can survive through diffusion alone. Complex organs such as kidneys, livers, and hearts need dense networks of blood vessels to deliver oxygen deep inside the tissue. Engineers are experimenting with nanopatterned surfaces and sacrificial inks that dissolve after printing to leave hollow channels behind.

Scaling and regulation also pose barriers. Growing a full-size human liver takes far more cells than current culture methods can reliably produce, and regulatory agencies are still developing frameworks for approving living, patient-specific implants.

Why It Matters

If tissue engineering fulfils its promise, the implications go beyond transplant waiting lists. Lab-grown tissues already serve as testing platforms for new drugs, reducing reliance on animal models. Engineered heart patches could repair damage after heart attacks without replacing the entire organ. And because lab-grown grafts can use a patient's own cells, they could drastically cut the cost and side effects of post-transplant immunosuppression.

The gap between 100,000 people in need and a limited supply of donors is not closing on its own. Tissue engineering offers medicine a way to build what nature cannot always provide.